 |
18 Diseases |  |
0 Trials |
|
0 Trials |  |
15 News |  |
- | lexaptepid pegol (NOX H94) / TME Pharma
Trial completion: Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients (clinicaltrials.gov) - Nov 24, 2015
P1/2, N=33, Completed, Sponsor: NOXXON Pharma AG
Active, not recruiting --> Completed
- | lexaptepid pegol (NOX H94) / TME Pharma
Enrollment closed, Trial primary completion date: Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients (clinicaltrials.gov) - Oct 6, 2015
P1/2, N=32, Active, not recruiting, Sponsor: NOXXON Pharma AG
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- | lexaptepid pegol (NOX H94) / TME Pharma
Enrollment change, Trial primary completion date: Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=32, Recruiting, Sponsor: NOXXON Pharma AG
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 N=20 --> 32 | Trial primary completion date: Nov 2014 --> Aug 2015
- | lexaptepid pegol (NOX H94) / TME Pharma
Enrollment open: Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients (clinicaltrials.gov) - May 27, 2014
P1/2, N=20, Recruiting, Sponsor: NOXXON Pharma AG
N=20 --> 32 | Trial primary completion date: Nov 2014 --> Aug 2015 Not yet recruiting --> Recruiting
- lexaptepid pegol (NOX H94) / TME Pharma
New P1/2 trial: Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients (clinicaltrials.gov) - Mar 4, 2014
P1/2, N=20, Not yet recruiting, Sponsor: Noxxon Pharma AG
- lexaptepid pegol (NOX H94) / TME Pharma
Enrollment change: Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer (clinicaltrials.gov) - Feb 20, 2014
P2a, N=12, Completed, Sponsor: Noxxon Pharma AG
Not yet recruiting --> Recruiting N=48 --> 12
- lexaptepid pegol (NOX H94) / TME Pharma
Trial completion: Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer (clinicaltrials.gov) - Feb 20, 2014
P2a, N=12, Completed, Sponsor: Noxxon Pharma AG
N=48 --> 12 Active, not recruiting --> Completed
- lexaptepid pegol (NOX H94) / TME Pharma
New P2a trial: Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer (clinicaltrials.gov) - Sep 20, 2012
P2a, N=12, Completed, Sponsor: Noxxon Pharma AG
- lexaptepid pegol (NOX H94) / TME Pharma
Trial completion: Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model (clinicaltrials.gov) - Apr 17, 2012
P1, N=24, Completed, Sponsor: Noxxon Pharma AG
Active, not recruiting --> Completed Active, not recruiting --> Completed
- lexaptepid pegol (NOX H94) / TME Pharma
Trial completion: First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94 (clinicaltrials.gov) - Mar 25, 2012
P1, N=64, Completed, Sponsor: Noxxon Pharma AG
Active, not recruiting --> Completed Recruiting --> Completed
- lexaptepid pegol (NOX H94) / TME Pharma
New P1 trial: Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model (clinicaltrials.gov) - Jan 30, 2012
P1, N=24, Completed, Sponsor: Noxxon Pharma AG